Briefly, the approach requires FC combinations with sufficient differences in antigen expression between normal and small abnormal populations (for example, expression of CD5 and decreased CD20 in the case of chronic lymphocytic leukemia/small lymphocytic lymphoma). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.